FSHR and ovarian cancer: However, preclinical studies suggest that blocking FSH-FSHR signaling with either FSH antagonists or FSHR antibodies is effective and safe to eliminate ovarian cancer in animal models (Blaakaer et al., 1995; Bordoloi et al., 2022; Perales-Puchalt et al., 2017).